Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-08-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (901 characters) from BeiGene, Ltd. regarding the date of the Audit Committee meeting to review and approve the company's interim results for the six months ended June 30, 2022. It references prior announcements of quarterly and half-year results and filings with the US SEC (Form 10-Q). The document states that the interim results will be published according to the Hong Kong Listing Rules and mentions reconciliation between US GAAP and IFRS. However, the document itself does not contain the financial results or detailed financial data, only the announcement of the meeting date and related procedural information. Given the short length and nature of the content, this fits the pattern of a Regulatory Filing (RNS) rather than the actual Interim Report (IR) or Earnings Release (ER).
2022-08-11 Chinese
港股公告：授出购股权
Director's Dealing Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the grant of stock options under the 2016 Option and Incentive Plan. It details the number of options granted, exercise price, vesting schedule, and other terms. The document is a regulatory announcement about a share-based compensation event, specifically the granting of stock options to an employee. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a full report but a specific disclosure related to share-based compensation. This fits the category of Director's Dealing (DIRS), which includes reports of personal share transactions or share-based awards by company directors or employees. The document is relatively short (2319 characters) and focused solely on the stock option grant. Therefore, the appropriate classification is DIRS with high confidence.
2022-08-09 Chinese
美股公告：表格S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 registration statement filed with the U.S. Securities and Exchange Commission (SEC) by BeiGene, Ltd. It registers additional shares under the company's 2016 Equity Incentive Plan. The document includes legal opinions, consent letters from auditors, registration fee calculations, and references to prior filings. It is a registration statement for securities issuance under an employee benefit plan, not a financial report, earnings release, or management discussion. Form S-8 filings are specifically related to registration of securities for employee benefit plans and fall under capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the filing itself, not just an announcement or certification, so it is not RPA or RNS.
2022-08-09 Chinese
百济神州有限公司自愿披露关于百泽安（替雷利珠单抗注射液）临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding clinical trial progress of their drug (Tislelizumab injection). It includes clinical trial results, risk warnings, and future plans to present data at academic conferences. The document is relatively short (1611 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement about clinical trial progress and potential regulatory approval risks, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a specific announcement about clinical trial progress and risk disclosure, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-08-09 Chinese
美股公告：季度报告10-Q表格
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC), as indicated by the header and the title '表格 10-Q' and references to the SEC and the Securities Exchange Act of 1934. It covers the quarterly period ending June 30, 2022, and includes detailed unaudited financial statements such as balance sheets, income statements, cash flow statements, and notes to the financial statements. The document also contains management discussion and analysis sections, risk factors, and other disclosures typical of a quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual quarterly report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q2 2022
2022-08-08 Chinese
港股公告：百济神州有限公司截至2022年6月30日止三个月及六个月未经审核业绩以及业务进展最新情况
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from BeiGene, Ltd. regarding its unaudited financial results for the three and six months ended June 30, 2022, including comprehensive financial data such as revenue, expenses, net loss, and detailed operational and business updates. It includes financial statements prepared under US GAAP, discusses business progress, clinical trial updates, and future milestones. The document is lengthy (over 13,000 characters) and contains substantive financial data and analysis, not merely an announcement or summary. It is not a certification or a brief announcement of report publication. The content aligns with an Interim / Quarterly Report, as it covers a period shorter than a full fiscal year with detailed financial statements and business commentary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2022
2022-08-04 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.